5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy (Q41722660)

From Wikidata

Jump to navigation Jump to search

scientific article published on February 1998

Language	Label	Description	Also known as
English	5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy	scientific article published on February 1998

Statements

scholarly article

1 reference

Europe PubMed Central

8 October 2017

1 reference

Europe PubMed Central

5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy (English)

1 reference

Europe PubMed Central

8 October 2017

1 reference

based on heuristic

inferred from title

author name string

Gregory RE

1

1 reference

Europe PubMed Central

8 October 2017

Ettinger DS

2

1 reference

Europe PubMed Central

8 October 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 February 1998

1 reference

Europe PubMed Central

8 October 2017

1 reference

Europe PubMed Central

8 October 2017

55

1 reference

Europe PubMed Central

8 October 2017

2

1 reference

Europe PubMed Central

8 October 2017

173-189

1 reference

Europe PubMed Central

8 October 2017

https://scigraph.springernature.com/pub.10.2165/00003495-199855020-00002

0 references

A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The neuropharmacology of emesis: the role of receptors in neuromodulation of nausea and vomiting.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The management of nausea and vomiting in clinical oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Ca

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—A randomised study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tropisetron. A review of the clinical experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are all 5-HT3 receptor antagonists the same?

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of Ondansetron with Customary Treatment in the Prophylaxis of Nausea and Emesis Induced by Non-Cisplatin Containing Chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The concept of selectivity in 5-HT receptor research

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Em

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron (OND) vs granisetron (GRA) in the control of chemotherapy induced acute emesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pharmacologic profile of oral granisetron (Kytril tablets).

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuroactive substances in the dorsal vagal complex of the medulla oblongata: nucleus of the tractus solitarius, area postrema, and dorsal motor nucleus of the vagus

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delayed emesis following anticancer chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urinary serotonin metabolite excretion during cisplatin chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The course of nausea and vomiting after high-dose cyclophosphamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proposal for classifying the acute emetogenicity of cancer chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuropharmacology of emesis induced by anti-cancer therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron and Tropisetron with Dexamethasone in the Prophylaxis of Acute Vomiting Induced by Non-cisplatin-Containing Chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methodology of antiemetic trials: a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimum management of nausea and vomiting in cancer chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiemetic efficacy and pharmacokinetic analyses of the serotonin antagonist ondansetron (GR 38032F) during multiple-day chemotherapy with cisplatin prior to autologous bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-HT3 receptors: pharmacologic and therapeutic aspects

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Tropisetron versus ondansetron in the prevention and control of emesis in patients undergoing chemotherapy with FAC/FEC for metastatic or surgically treated breast carcinoma].

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of antiemetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9506240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-199855020-00002

1 reference

Europe PubMed Central

8 October 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

8 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41722660&oldid=1926280055"